Introduction: The potential of a radioiodine-labeled, anti-adenosine triphosphate synthase monoclonal antibody (ATPS mAb) as a theragnostic agent for simultaneous cancer imaging and treatment was evaluated. Methods: Adenosine triphosphate synthase monoclonal antibody was labeled with radioiodine, then radiotracer uptake was measured in 6 different cancer cell lines. In vivo biodistribution was evaluated 24 and 48 hours after intravenous injection of
I-ATPS mAb into MKN-45 tumor-bearing mice (n ¼ 3). For radioimmunotherapy, 18.5 MBq

131
I-ATPS mAb (n ¼ 7), isotype immunoglobulin G (IgG) (n ¼ 6), and vehicle (n ¼ 6) were injected into MKN-45 tumor-bearing mice for 4 weeks, and tumor volume and percentage of tumor growth inhibition (TGI) were compared each week. Results: MKN-45 cells showed the highest in vitro cellular binding after 4 hours (0.00324 + 0.00013%/mg), which was significantly inhibited by unlabeled ATPS mAb at concentrations of greater than 0.4 mM. The in vitro retention rate of 125 I-ATPS mAb in MKN-45 cells was 64.1% + 1.0% at 60 minutes. The highest tumor uptake of 125 I-ATPS mAb in MKN-45 tumor-bearing mice was achieved 24 hours after injection (6.26% + 0.47% injected dose [ID]/g), whereas tumor to muscle and tumor to blood ratios peaked at 48 hours. The 24-hour tumor uptake decreased to 3.43% + 0.85% ID/g by blocking with unlabeled ATPS mAb. After 4 weeks of treatment, mice receiving
Introduction
Solid tumors require new vessel formation, a process called angiogenesis, to grow and metastasize. 1 Whether tumor growth is aggravated or inhibited is dependent on the balance between proangiogenic and antiangiogenic factors. Angiostatin is a potent, intrinsic antiangiogenic factor that can reverse the "angiogenic switch." 2 Researchers have found that adenosine triphosphate (ATP) synthase is not only located in the mitochondrial inner membrane but also on the surface membrane of endothelial and tumor cells. 3, 4 Ectopic ATP synthase a/b subunits have been confirmed experimentally as a binding site for angiostatin; therefore, ectopic ATP synthase is a potential target of antiangiogenic therapy. 5 Angiostatin itself inhibits the ATP hydrolytic activity of F 1 ATP synthase (extramembranous component); in addition, a polyclonal antibody against the asubunit of ATP synthase blocked the binding of angiostatin and abrogated its inhibitory effect on endothelial proliferation. 3, 6 A monoclonal antibody to the b catalytic subunit of ATP synthase inhibited the hydrolytic activity and ATP generation by ATP synthase on the surface of endothelial cells, consequently disrupting endothelial cell tube formation and neovascularization. 7 Moreover, preventing ATP synthase activity can prevent the proliferation and migration of breast cancer cells and enhance the cytotoxic effects of doxorubicin. 8 Thus, monoclonal antibodies against ATP synthase are good candidates for antiangiogenic treatment.
Radioimmunotherapy has become a promising anticancer strategy ever since the therapeutic efficacy of a specific carcinoembryonic antigen-radiolabeled antibody was reported in 1981. 9 Among the various radioisotopes, radioiodine was the first to be used as an antibody-linked label for imaging and therapeutic purposes. 10 With regard to the imaging of F 1 F O ATP synthase using radioisotopes, researchers have already demonstrated that radioiodine-labeled angiostatin can be used for this purpose. [12] [13] [14] However, a direct labeling method showed limited in vivo stability, and a modified labeling method using a Bolton-Hunter reagent exhibited insufficient labeling efficiency; thus, the method still needs some improvement. 12, 13 Therefore, in the present study, an anti-ATP synthase monoclonal antibody (ATPS mAb) was labeled, 8 and its potential as an angiogenesis-targeting theragnostic agent was evaluated through in vitro and in vivo analyses.
Materials and Methods
Radioiodination of ATPS mAb
Adenosine triphosphate synthase monoclonal antibody was purchased from Abcam (MW 52 kDa, Cambridge, Massachusetts) and stored as aliquots at À78 C. Na 125 I and Na 131 I were obtained from PerkinElmer (Waltham, Massachusetts) and the Korea Atomic Energy Research Institute (Daejeon, Korea), respectively. For radioiodination, the Iodogen tube (Pierce Biotechnology, Rockford, Illinois) method was applied as described previously. 15 12, 13 and cells were then incubated for 1, 2, or 4 hours at 37 C and 5% CO 2 . After incubation, the cells were washed twice with cold PBS and harvested with 0.1 N NaOH. Radioactivity of the cells was counted using a Cobra II multichannel g counter (PerkinElmer Inc) and normalized to cell protein content obtained using the Bradford method. 
Western Blot Analysis for ATP Synthase in MKN-45 Cells
For Western blot analysis of anti-ATPS mAb, total membrane proteins and plasma membrane proteins were extracted using Minute plasma membrane protein isolation kit (Invent Biotechnologies, Inc, Plymouth, Minnesota) according to the manufacturer's instruction. The protein content was measured using a microplate reader and the Pierce-660 solution (Thermo Fisher Scientific, Waltham, Massachusetts). Samples (5 mg) were loaded on a 12% polyacrylamide gel and transferred to nitrocellulose membranes (Hybond ECL; Amersham Biosciences, Piscataway, New Jersey). The membranes were blocked with 5% skim milk and incubated overnight with anti-ATPS mAb at 4 C and then with an horseradish peroxide-linked secondary antibody (1:5000; Amersham Bioscience). The protein bands were finally visualized with enhanced chemiluminescence reagents (Amersham Bioscience) and exposure to an X-ray film (Agfa, Mortsel, Belgium). The intensity of bands was measured using ImageJ software (version 1.5).
In Vivo g Camera Imaging, Biodistribution Study, and Blocking Study of 125 I-ATPS mAb in MKN-45 Tumor-Bearing Mice
For g camera imaging, MKN-45 tumor-bearing mice (n ¼ 5) were injected intravenously with 3.7 MBq 125 I-ATPS mAb (1 mg antibody). At 2, 24, and 48 hours after injection, static planar images were acquired using a g camera (Orbiter; Siemens, Erlangen, Germany) fitted with a pinhole collimator (Siemens). Mice were scanned for 20 minutes in a prone position under inhalation anesthesia using isoflurane, and the matrix size was 256 Â 256.
MKN-45 tumor-bearing mice (n ¼ 3 for each time point) received an injection of 1.85 MBq 125 I-ATPS mAb through the tail vein and were killed for biodistribution at 24 and 48 hours after injection. Major organs as well as blood and tumors were dissected, weighed, and counted for radioactivity using a Gamma HES (g counter; Shin Jin Medics Inc, Seoul, Korea). Uptake in the organs and tumors was expressed as the percentage of the injected dose per gram tissue (% ID/g). For blocking study, 25 mg cold ATPS mAb, 50 times larger than the dosage of radiolabeled ATPS mAb, was coinjected with 1.85 MBq 125 I-ATPS mAb through the tail vein and then organs were removed at 24 hours after injection.
Radioimmunotherapy With 131 I-ATPS mAb in Tumor Xenograft Model and 2-deoxy-2-[ 18 F]fluoro-D-glucose Positron Emission Tomography Imaging
The therapeutic efficacy of 131 I-ATPS mAb was evaluated in mice using MKN-45 tumor xenografts. Mice received an intravenous injection of 18.5 MBq 131 I-ATPS mAb (n ¼ 7), 5 mg of isotype immunoglobulin G (IgG) (n ¼ 6; SigmaAldrich, St Louis, Missouri), and vehicle (n ¼ 6, normal saline), respectively, once a week for 4 weeks. 19 The number of animals in each group was determined by a crude method based on law of diminishing return. 20 Tumor size was measured weekly in 2 dimensions (length and width) using a caliper. Tumor volume was calculated by the formula, V ¼ (length Â width 2 )/2, 21 and compared between the 2 groups. To evaluate the antitumor effect, tumor growth inhibition (TGI) was determined each week using the formula:
where T t and C t are the tumor volumes of the treated and control groups at time t, respectively, whereas T 0 and C 0 are those at baseline. A median %TGI of at least 50% was considered as the cutoff for a significant antitumor effect. For imaging purpose, positron emission tomography (PET) images were acquired 1 hour after an intravenous injection of 18.5 MBq 2-deoxy-2-[ 
Statistical Analysis
All data are presented as means + standard errors. The statistical comparison of cellular uptake and tumor size was evaluated by Student t test and Kruskal-Wallis test using statistical software (R, version 3.1.2), and the difference was considered significant at P < .05.
Results
Radioiodination of ATPS mAb
The radiochemical yield of 125 I-ATPS mAb increased gradually with the dosage of ATPS mAb: 47.5% + 4.0%, 69.0% + 0.9%, 74.4% + 0.7%, 75.9% + 1.9%, and 91.5% + 1.3% at 5, 10, 20, 40, and 80 mg, respectively ( Figure 1A ). This pattern was the same when using 131 I-ATPS mAb: 4.3% + 0.9%, 17.3% + 1.5%, 36.7% + 3.0%, 43.3% + 3.2%, and 52.0% + 2.0% at 5, 10, 20, 40, and 80 mg, respectively ( Figure 1B ). Throughout the current study, the labeling efficiency of 125 I-ATPS mAb was better than that of 131 I-ATPS mAb. The entire labeling procedure was completed within 45 minutes.
In Vitro Cellular Uptake and Retention Rate
The cellular uptake of 125 I-ATPS mAb was measured in various cancer cell lines (Figure 2A ). MKN-45 cells showed the highest cellular uptake at 2 hours (0.00122 + 0.00009%/mg) and 4 hours (0.00324 + 0.00013%/mg). The MKN-45 cellular uptake at 4 hours was significantly higher than that in the other cell lines (1.8-to 6.2-fold, all P < .05). Based on these results, MKN-45 cells were selected for subsequent experiments. Western blot analysis (D) for adenosine triphosphate synthase was performed using anti-ATPS mAb. Protein bands were visualized for both total membranes and plasma membranes at 57 kDa (estimated by prestained protein marker). The intensity of band was 4.5 times higher for plasma membrane proteins than for total membrane proteins. *P < .05 compared to untreated control. Error bar ¼ standard error. ATPS mAb indicates adenosine triphosphate synthase monoclonal antibody. 
Expression of ATP Synthase in MKN-45 Cells
Western blot analysis using anti-ATPS mAb revealed that the expression of ATP synthase was 4.5 times higher for plasma membranes than for total membranes ( Figure 2D ). The plasma membrane fraction was 20.0% of total membrane fraction by protein analysis. Therefore, the majority of ATP synthase was expressed on the surface of MKN-45 cells (plasma membranes to mitochondria ratio ¼ 9:1).
g Camera Imaging and Biodistribution of 125 I-ATPS mAb in MKN-45 Tumor-Bearing Mice On g camera images, tumor uptake was discernible from 24-hour images, and the tumor to background contrast became more pronounced at 48 hours ( Figure 3A) . Thyroid uptake Figure 3B and Table 1 . The biodistribution data at 2 hours were omitted because no tumor or thyroid uptake was visualized on g camera images. The highest tumor uptake was achieved 24 hours postinjection (6.26% + 0.47% ID/g) and had decreased by 48 hours (1.50 + 0.23% ID/g). On the other hand, tumor to muscle and tumor to blood ratios increased over time ( Figure 3C ), although the difference was not statistically significant. Tumor to muscle ratios were 2.79 + 0.37 and 4.31 + 1.22 at 24 and 48 hours, respectively, and tumor to blood ratios were 0.51 + 0.04 and 0.77 + 0.21 at 24 and 48 hours, respectively.
The radioactivity of the bladder was high at 24 hours (21.36 + 2.34% ID/g) but declined markedly at 48 hours (1.69 + 0.85% ID/g). The radioactivity of the other organs also decreased gradually with time.
After blocking with unlabeled ATPS mAb, tumor uptake at 24 hours significantly decreased to 3.43 + 0.85% ID/g ( Figure  3B and Table 1 , P ¼ .0437, compared to tumor uptake at 24 hours without blocking). Similarly, tumor/muscle ratio and tumor/blood ratio also decreased significantly to 0.81 + 0.30 (P ¼ .0141) and 0.07 + 0.02 (P ¼ .0006), respectively. 
Radioimmunotherapy
Discussion
In this study, ATPS mAb was labeled with radioiodine to develop a theragnostic agent against tumor angiogenesis. Among the various cancer cells evaluated, MKN-45 cells showed the highest and most specific uptake of 125 I-ATPS mAb. In a biodistribution study, xenograft uptake of 125 I-ATPS mAb peaked at 24 hours after intravenous injection; however, the contrast between tumor and background was optimal for analysis 48 hours after injection. Furthermore, 131 I-ATPS mAb treatment significantly suppressed the growth of MKN-45 xenografts in mice, which demonstrated the potential of ATPS mAb for radioimmunotherapy. To our knowledge, this is the first study that has evaluated the feasibility of using a radiolabeled monoclonal antibody targeting ATP synthase for imaging and tumor angiogenesis prevention.
Angiostatin is a well-known and potent angiostatic factor that inhibits the growth of preexisting micrometastases. However, angiostatin treatment requires daily injection without interruption and is difficult to produce; thus, the future of angiostatin therapy for clinical use may be limited. 22 Instead of angiostatin, recent research has focused on ectopic ATP synthase as an antiangiogenic target after it was identified as the receptor for angiostatin. 7, 8 Radioiodinated angiostatin was the first radiotracer produced that was based on the binding of angiostatin to ectopic F 1 F O ATP synthase. 3 The specific binding of 125 I-angiostatin to cell surface F 1 F O ATP synthase was shown in human umbilical vein endothelial cells and human colon cancer cells. 14 Radioiodine can be attached to angiostatin either by lactoperoxidase catalysis or through covalent coupling using Bolton-Hunter reagent. 12, 13 Direct labeling of angiostatin showed modest labeling efficiencies ranging from 40% to 70%. 12 However, the in vivo stability of radioiodinated angiostatin was so poor that thyroid uptake by deiodination appeared on g camera images as early as 1 hour after intravenous injection. The in vivo stability of radioiodinated angiostatin was markedly improved by the Bolton-Hunter method (thyroid uptake ¼ 15.47 + 7.74% ID/g) compared with the direct labeling method (430.87 + 32.17% ID/g). 13 However, the average labeling efficiency was only 20%. In comparison, the radioiodinated ATPS mAb in this study showed similar level of labeling efficiencies (76%-95% for 125 I and 43%-52% for 131 I at 40-80 mg antibody) and better in vivo stability compared to the direct labeling method. Thyroid uptake of 125 I-ATPS mAb was not obvious at 2 hours but became prominent after 24 hours on g camera images. In terms of the labeling efficiency and stability, radioiodinated ATPS mAb could be an effective substitute for radioiodinated angiostatin. We also have performed the indirect radioiodination of anti-ATPS mAb using Bolton-Hunter reagent; however, we failed to conjugate it to the antibody. Free radioiodine uptake by nontarget organs can be blocked by iodide solution, which is currently used in the clinic. Therefore, the direct radioiodination is a clinically applicable labeling method for anti-ATPS mAb.
In this study, early renal excretion of 125 I-ATPS mAb was demonstrated during the biodistribution analysis. Bladder radioactivity was 21.36 + 2.34% ID/g at 24 hours but dropped to 1.69 + 0.85% ID/g at 48 hours, which may be due to the renal excretion of free iodide from the deiodination of 125 I-ATPS mAb. Liver uptake was also high at 24 hours (13.47 + 0.74% ID/g) and it decreased to 8.61 + 0.77% ID/g at 48 hours. The b-chain of ATP synthase was recently found to be expressed on the surface of hepatocytes and serves as a high-density lipoprotein receptor for apolipoprotein A-I. 23 Therefore, liver uptake of 125 I-ATPS mAb could be partly attributed to binding to ATP synthase on the surface of hepatocytes. However, in the presence of deiodination, liver can accumulate and metabolize radiolabeled thyroid hormones that are produced by functioning thyroids. 24 One report also suggested that the uptake of circulating antigen-antibody complexes is the primary mechanism for hepatocytes to uptake radiolabeled antibodies. 25 Therefore, the liver uptake of radioiodinated ATPS mAb imaging may not be attributed to a single mechanism. 31 However, according to our preliminary results, the labeling of 124 I-ATPS mAb is a challenging work because of its low radiochemical yield and specific activity.
Using long-lived radioisotopes and the forced clearance of unbound radiopharmaceuticals are important to enhance the quality of monoclonal antibody images. In this study, while 125 I-ATPS mAb attained a peak tumor uptake after 24 hours, the maximal tumor to background ratio was achieved after 48 hours. A previous report showed that the clearance rate of IgG monoclonal antibodies is influenced by serum concentration. 32 Intravenous injection of immunoglobulin enhanced the clearance of monoclonal antibodies *2-fold through the saturation of the FcRn salvage receptor. 33 Therefore, pretreatment with immunoglobulin may be a possible strategy to achieve an early tumor to background peak for radioiodinated ATPS mAb.
Radioimmunotherapy is a novel anticancer treatment based on antibody-mediated specific delivery of radiation to improve therapeutic efficacy and minimize toxicity to normal tissues. Radiolabeled anti-CD20 monoclonal antibodies such as Bexxar and Zevalin have been approved for clinical use in non-Hodgkin's lymphoma after ascertaining the therapeutic efficacy as a single agent. [34] [35] [36] [37] However, radioimmunotherapy for solid tumors has been only a partial success in patients with minimal residual disease and micrometastasis and needs to be optimized further. 38, 39 We evaluated the antitumor effect of 131 I-ATPS mAb in stomach cancer-xenografted mice. The results showed that 131 I-ATPS mAb significantly suppressed tumor growth in comparison with isotype IgG or vehicle after 4 weeks. The amount of mAb used for radioimmunotherapy in this study is only 5 mg, which was too small to exert therapeutic effects on the tumor growth compared to the previous reports. 40, 41 Therefore, the inhibitory effect on the tumor growth during the radioimmunotherapy probably came from b-radiation, not from mAb itself. The %TGI was greater than 50% during the first week of treatment and then increased with repeated treatment. Targeting angiogenesis for the treatment of stomach cancer has been attempted clinically using several different types of antiangiogenic agents: ligands for vascular endothelial growth factor (VEGF), VEGF receptor 2 antagonists, and receptor tyrosine kinase inhibitors. 42 The survival benefit of the VEGF ligand has only been shown in Western countries and not in the general population. Receptor tyrosine kinases also showed no therapeutic effects as single agents and have so far not been entered into stage III clinical trials. Among these treatments, only the VEGF receptor 2 antagonist ramucirumab had an effect both as a single agent and in combination with paclitaxel, regardless of race. Therefore, the development of a new antiangiogenesis therapy with a different target is essential for stomach cancer. Results from this study suggest that radioiodinated ATPS mAb is a good candidate for antiangiogenic treatment in stomach cancer.
Using whole mouse IgG for ATP synthase is a limitation of this study. As mentioned above, the long-term blood circulation, up to 3 weeks in humans, is a problematic characteristic of whole antibodies and results in high background in imaging and significant toxicity to normal tissues. 43 In addition, the human antimouse antibody response is also a problem encountered when using mouse monoclonal antibodies. Low in vivo stability of radioiodinated ATPS and the subsequent high thyroid uptake also need to be improved, although it was better than that of radioiodinated angiostatin. Researchers have developed various engineered antibodies by downsizing, multimerization, or humanization to improve circulation, binding affinity, tissue penetration, and in vivo stability. [44] [45] [46] This is a preliminary study to investigate the feasibility of using ATPS mAb for both radionuclide imaging and radioimmunotherapy; therefore, further technical enhancement is necessary before a radioiodinated ATPS mAb can be tested in clinics.
Conclusion
Adenosine triphosphate synthase monoclonal antibody was labeled with radioiodine with a sufficient radiochemical yield and showed a specific uptake and therapeutic effect in stomach cancer. Although the feasibility of radioiodinated ATPS mAb as a theragnostic agent targeting angiogenesis was proven in this study, further studies are needed to improve the biodistribution and therapeutic efficacy.
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